24/7 Market News Snapshot 29 July, 2025 – Atossa Therapeutics, Inc. Common Stock (NASDAQ:ATOS)

July 29, 2025

DENVER, Colo., 29 July, 2025 (www.247marketnews.com) – (NASDAQ:ATOS) are discussed in this article.
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is experiencing a notable bullish trend, currently trading at approximately $0.915, reflecting a 12% increase from the previous close of $0.817 in pre-market activity. This significant rise is accompanied by a trading volume of 5.83 million shares, indicating increased investor interest and positive market sentiment towards the company’s growth potential. Market observers are urged to keep an eye on key resistance levels and any forthcoming news that may impact the stock’s trajectory. With this bullish momentum, ATOS appears well-positioned for further advancement in the current market landscape.

In a positive development for the company, Atossa has received constructive written feedback from the U.S. Food and Drug Administration (FDA) regarding a proposed dose optimization trial for (Z)-endoxifen, an innovative treatment targeting estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. The FDA’s response affirms critical elements of Atossa’s clinical development plan, allowing the company to proceed without a scheduled virtual meeting and paving the way for a planned Investigational New Drug (IND) submission by the fourth quarter of 2025.

Dr. Steven Quay, Chief Executive Officer and Chairman of the Board, noted that this feedback marks a pivotal milestone for Atossa, reinforcing confidence in their clinical strategy. The FDA’s endorsement encompasses the proposed dosing optimization approach, supports the rationale for the combination of (Z)-endoxifen with established therapies, and confirms adequate nonclinical safety data to advance without additional toxicity studies. Furthermore, the cardiac safety assessment plan for the monotherapy phase of the trial has received approval.

Atossa is now poised to expedite the clinical development of (Z)-endoxifen, focused on enhancing treatment options for patients facing metastatic breast cancer. The company plans to release detailed information regarding the trial design and targeted patient populations in the near future, continuing its commitment to scientific innovation and improving patient outcomes in the breast cancer treatment landscape.

Related news for (ATOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.